Drugs / MSI-78
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT01594762 | Jun 2014 → Jul 2016 | — | Dipexium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01590758 | Jun 2014 → Aug 2016 | — | Dipexium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT00563433 Comparator | Aug 1994 → Jul 1996 | ulcer of lower limbs | Abeona Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT00563394 Comparator | Aug 1994 → Jul 1996 | ulcer of lower limbs | Abeona Therapeutics, Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSI-78 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00563433 ↗ |
| Known as | pexiganan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01590758 ↗ |
| Modality | Peptide | “Antimicrobial peptides under clinical trial: Pexiganan (NCT01594762” PMID 36781451 ↗ Feb 2023 |
| Route | Topical | “topically applied magainin peptide (MSI-78)” NCT00563394 ↗ |